Evolving diagnostic and prognostic imaging of the various cardiomyopathies

Annals of the New York Academy of Sciences

Volumn 1254, Issue 1, 2012, Pages 123-130

  Sanz, Javier ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Computed tomography; Imaging; Magnetic resonance; Nuclear medicine

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; RADIOISOTOPE;

ADRENERGIC SYSTEM; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CAUSE OF DEATH; CHAGAS DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATION; DIAGNOSTIC ACCURACY; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IRON OVERLOAD; ISCHEMIC CARDIOMYOPATHY; MYOCARDITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDIAL EFFUSION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TAKOTSUBO CARDIOMYOPATHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 84860470985     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06490.x     Document Type: Article

References (50)

1. Allman, K.C. et al 2002. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J. Am. Coll. Cardiol. 39: 1151-1158.
2. Bonow, R.O. et al 2011. Myocardial viability and survival in ischemic left ventricular dysfunction. N. Engl. J. Med. 364: 1617-1625.
3. Perez-David, E. et al 2011. Noninvasive identification of ventricular tachycardia-related conducting channels using contrast-enhanced magnetic resonance imaging in patients with chronic myocardial infarction: comparison of signal intensity scar mapping and endocardial voltage mapping. J. Am. Coll. Cardiol. 57: 184-194.
4. Heidary, S. et al 2010. Quantitative tissue characterization of infarct core and border zone in patients with ischemic cardiomyopathy by magnetic resonance is associated with future cardiovascular events. J. Am. Coll. Cardiol. 55: 2762-2768.
5. Boye, P. et al 2011. Prediction of life-threatening arrhythmic events in patients with chronic myocardial infarction by contrast-enhanced CMR. JACC Cardiovasc. Imaging 4: 871-879.
6. Delgado, V. et al 2011. Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation 123: 70-78.
7. Eitel, I. et al 2011. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. Circ. Cardiovasc. Imaging 4: 354-362.
8. Ganame, J. et al 2009. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur. Heart. J. 30: 1440-1449.
9. Ghostine, S. et al 2008. Non-invasive diagnosis of ischaemic heart failure using 64-slice computed tomography. Eur. Heart J. 29: 2133-2140.
10. McCrohon, J.A. et al 2003. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108: 54-59.
11. Assomull, R.G. et al 2011. Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology. Circulation 124: 1351-1360.
12. Cheong, B.Y. et al 2009. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation 120: 2069-2076.
13. Klem, I. et al 2011. Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. Circ. Cardiovasc. Imaging 4: 610-619.
14. Lehrke, S. et al 2011. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97: 727-732.
15. Iles, L. et al 2011. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J. Am. Coll. Cardiol. 57: 821-828.
16. Flett, A.S. et al 2011. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122: 138-144.
17. Jacobson, A.F. et al 2010. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J. Am. Coll. Cardiol. 55: 2212-2221.
18. Pantazis, A.A. & P.M. Elliott 2009. Left ventricular noncompaction. Curr. Opin. Cardiol. 24: 209-213.
19. Kohli, S.K. et al 2008. Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? Eur. Heart J. 29: 89-95.
20. Jacquier, A. et al 2010. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur. Heart J. 31: 1098-1104.
21. Chaowu, Y., L. Li & Z. Shihua 2011. Histopathological features of delayed enhancement cardiovascular magnetic resonance in isolated left ventricular noncompaction. J Am Coll Cardiol. 58: 311-312.
22. Youssef, G. et al 2011. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 97: 2078-2087.
23. Patel, M.R. et al 2009. Detection of myocardial damage in patients with sarcoidosis. Circulation 120: 1969-1977.
24. Tahara, N. et al 2011. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc. Imaging 3: 1219-1228.
25. Baccouche, H. et al 2009. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. Eur. Heart J. 30: 2869-2879.
26. Schultheiss, H.P., U. Kuhl & L.T. Cooper 2011. The management of myocarditis. Eur. Heart J. 32: 2616-2625.
27. Friedrich, M.G. et al 2009. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J. Am. Coll. Cardiol. 53: 1475-1487.
28. Monney, P.A. et al 2011. Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis. Heart 97: 1312-1318.
29. Eitel, I. et al 2011. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 306: 277-286.
30. Kremastinos, D.T. & D. Farmakis 2011. Iron overload cardiomyopathy in clinical practice. Circulation 124: 2253-2263.
31. Carpenter, J.P. et al 2011. On T2* magnetic resonance and cardiac iron. Circulation 123: 1519-1528.
32. Kirk, P. et al 2009. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120: 1961-1968.
33. Gersh, B.J. et al 2011. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 58: e212-e260.
34. Bruder, O. et al 2010. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 56: 875-887.
35. O'Hanlon, R. et al 2010. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 56: 867-874.
36. Rubinshtein, R. et al 2010. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ. Heart Fail. 3: 51-58.
37. Maron, M.S. et al 2008. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ. Heart Fail 1: 184-191.
38. Dubrey, S.W., P.N. Hawkins & R.H. Falk 2010. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 97: 75-84.
39. Koyama, J. & R.H. Falk 2010. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc. Imaging 3: 333-342.
40. Syed, I.S. et al 2010. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3: 155-164.
41. Austin, B.A. et al 2009. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc. Imaging 2: 1369-1377.
42. Niemann, M. et al 2011. Differences in fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc. Imaging 4: 592-601.
43. Basso, C. et al 2009. Arrhythmogenic right ventricular cardiomyopathy. Lancet 373: 1289-1300.
44. Sen-Chowdhry, S. et al 2007. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 115: 1710-1720.
45. Marcus, F.I. et al 2010. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 121: 1533-1541.
46. Quarta, G. et al 2011. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation 123: 2701-2709.
47. Vermes, E. et al 2011. Impact of the revision of arrhythmogenic right ventricular cardiomyopathy/dysplasia task force criteria on its prevalence by CMR criteria. JACC Cardiovasc. Imaging 4: 282-287.
48. Verhaert, D. et al 2011. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc. Imaging 4: 67-76.
49. Rochitte, C.E. et al 2005. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J. Am. Coll. Cardiol. 46: 1553-1558.
50. Salemi, V.M. et al 2011. Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. Circ Cardiovasc Imaging 4: 304-311.